首页|Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies
Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Low grade inflammation is associated with the progression of atherosclerosis. Patients with type 2 diabetes (T2D) have altered cholesterol levels, which are targeted by free radicals to promote lipid peroxidation. Elevated levels of monocyte-associated cytokines such as interleukin (IL)-6, monocyte chemoattractant protein 1 (MCP-1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and tumor necrosis factor-alpha (TNF-α), subsequently drive endothelial tissue injury. In fact, the levels of circulating platelet-monocyte aggregates in patients with T2D is a robust marker for atherosclerosis and a cardiovascular disease (CVD)-risk factor. To identify eligible studies, we searched the major online databases using PubMed and Google Scholar. The cumulative evidence synthesized in the current review suggests that, traditional therapies which include thiazo-lidinediones, statins and some calcium channel blockers can be useful in the primary prevention of atherosclerosis by inhibiting the formation of monocyte-derived microparticles, and pro-inflammatory cytokines such as IL-6, TNF-α, MCP-1, and NF-κB in patients with T2D. Future studies are needed to ascertain whether the combination of dietary interventions and glucose or lipid lowering agents can provide an enhanced car-dioprotection in patients with T2D.
Type 2 diabetesCardiovascular diseaseVascular functionMonocytesInflammation.Therapeutic target
Siphamla R. Ngcobo、Bongani B. Nkambule、Tawa M. Nyambuya、Kabelo Mokgalaboni、Aviwe Ntsethe、Vuyolwethu Mxinwa、Khanyisani Ziqubu、Yonela Ntamo、Thembeka A. Nyawo、Phiwayinkosi V. Dludla
展开 >
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4000, South
NSTL
